{"id":3551,"date":"2022-08-17T14:54:02","date_gmt":"2022-08-17T11:54:02","guid":{"rendered":"https:\/\/info.e-med.co.il\/remsima\/?p=3551"},"modified":"2023-10-25T14:57:05","modified_gmt":"2023-10-25T11:57:05","slug":"effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/","title":{"rendered":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study"},"content":{"rendered":"<h3 class=\"title\" dir=\"ltr\" style=\"text-align: left;\">Abstract<\/h3>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p dir=\"ltr\" style=\"text-align: left;\"><strong class=\"sub-title\">Background and aims:\u00a0<\/strong>We assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensified intravenous regimen.<\/p>\n<p style=\"text-align: right;\"><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35987302\/\" target=\"_blank\" rel=\"noopener\">\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/strong><\/p>\n<\/div>\n<p dir=\"ltr\">Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, Laugie M, Manlay L, Mathieu N, Pereira B, Fumery M. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. doi: 10.1016\/j.cgh.2022.08.011. Epub 2022 Aug 17. PMID: 35987302.<\/p>\n","protected":false},"excerpt":{"rendered":"<p dir=\"ltr\"><strong>Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346<\/strong><\/p>\n","protected":false},"author":2,"featured_media":3552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[28,26,24],"tags":[],"class_list":["post-3551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"&#039;\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3&#039;\"\/>\n\t<meta name=\"keywords\" content=\"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"he_IL\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima\" \/>\n\t\t<meta property=\"og:description\" content=\"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2022-08-17T11:54:02+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2023-10-25T11:57:05+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#article\",\"name\":\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima\",\"headline\":\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study\",\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/colorectalcancer.jpg\",\"width\":478,\"height\":359,\"caption\":\"colon\"},\"datePublished\":\"2022-08-17T14:54:02+03:00\",\"dateModified\":\"2023-10-25T14:57:05+03:00\",\"inLanguage\":\"he-IL\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#webpage\"},\"articleSection\":\"Article, \\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd, \\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"position\":2,\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"position\":3,\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#listItem\",\"name\":\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#listItem\",\"position\":4,\"name\":\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\",\"name\":\"\\u05e4\\u05d0\\u05d3\\u05d0\\u05d2\\u05d9\\u05e1 \\u05d9\\u05e9\\u05e8\\u05d0\\u05dc \\u05e1\\u05d5\\u05db\\u05e0\\u05d5\\u05d9\\u05d5\\u05ea \\u05d1\\u05e2\\\"\\u05de\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/11\\\/remsima_150.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#organizationLogo\",\"width\":150,\"height\":150},\"image\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/\",\"name\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#webpage\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/\",\"name\":\"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima\",\"description\":\"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346\",\"inLanguage\":\"he-IL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/colorectalcancer.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#mainImage\",\"width\":478,\"height\":359,\"caption\":\"colon\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\\\/#mainImage\"},\"datePublished\":\"2022-08-17T14:54:02+03:00\",\"dateModified\":\"2023-10-25T14:57:05+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"name\":\"Remsima\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"inLanguage\":\"he-IL\",\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima","description":"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346","canonical_url":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/","robots":"max-image-preview:large","keywords":"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#article","name":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima","headline":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study","author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/colorectalcancer.jpg","width":478,"height":359,"caption":"colon"},"datePublished":"2022-08-17T14:54:02+03:00","dateModified":"2023-10-25T14:57:05+03:00","inLanguage":"he-IL","mainEntityOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#webpage"},"isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#webpage"},"articleSection":"Article, \u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd, \u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"},{"@type":"BreadcrumbList","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","position":1,"name":"Home","item":"https:\/\/info.e-med.co.il\/remsima","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","position":2,"name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","position":3,"name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/research\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#listItem","name":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#listItem","position":4,"name":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study","previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"}}]},{"@type":"Organization","@id":"https:\/\/info.e-med.co.il\/remsima\/#organization","name":"\u05e4\u05d0\u05d3\u05d0\u05d2\u05d9\u05e1 \u05d9\u05e9\u05e8\u05d0\u05dc \u05e1\u05d5\u05db\u05e0\u05d5\u05d9\u05d5\u05ea \u05d1\u05e2\"\u05de","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","url":"https:\/\/info.e-med.co.il\/remsima\/","logo":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/11\/remsima_150.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#organizationLogo","width":150,"height":150},"image":{"@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author","url":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/","name":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'","image":{"@type":"ImageObject","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g","width":96,"height":96,"caption":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'"}},{"@type":"WebPage","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#webpage","url":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/","name":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima","description":"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346","inLanguage":"he-IL","isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#website"},"breadcrumb":{"@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#breadcrumblist"},"author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"creator":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/colorectalcancer.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#mainImage","width":478,"height":359,"caption":"colon"},"primaryImageOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/#mainImage"},"datePublished":"2022-08-17T14:54:02+03:00","dateModified":"2023-10-25T14:57:05+03:00"},{"@type":"WebSite","@id":"https:\/\/info.e-med.co.il\/remsima\/#website","url":"https:\/\/info.e-med.co.il\/remsima\/","name":"Remsima","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","inLanguage":"he-IL","publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"}}]},"og:locale":"he_IL","og:site_name":"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","og:type":"article","og:title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima","og:description":"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346","og:url":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/","article:published_time":"2022-08-17T11:54:02+00:00","article:modified_time":"2023-10-25T11:57:05+00:00","twitter:card":"summary","twitter:title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study | Remsima","twitter:description":"Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346"},"aioseo_meta_data":{"post_id":"3551","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_custom_image_width":null,"og_custom_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"none","tabs":null,"priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"created":"2023-10-25 11:53:59","updated":"2026-05-15 00:39:37","primary_term":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"twitter_image_url":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"limit_modified_date":false,"ai":null,"seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/updates-news\/\" title=\"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\">\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/research\/\" title=\"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd\">\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tEffectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/info.e-med.co.il\/remsima"},{"label":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/"},{"label":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/research\/"},{"label":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study","link":"https:\/\/info.e-med.co.il\/remsima\/effectiveness-of-switching-from-intravenous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-diseases-the-remswitch-study\/"}],"_links":{"self":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/comments?post=3551"}],"version-history":[{"count":1,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3551\/revisions"}],"predecessor-version":[{"id":3553,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3551\/revisions\/3553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media\/3552"}],"wp:attachment":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media?parent=3551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/categories?post=3551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/tags?post=3551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}